CD74 and intratumoral immune response in breast cancer

Wang, Zhiqiang; Milne, Katy; Derocher, Heather; Webb, John R.; Nelson, Brad H.; Watson, Peter H.

doi:10.18632/oncotarget.8610

Cited by 115 publications

(38 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relation between PD-L1 and the levels and localization of CD8, CD4, and CD68 TIL was assessed (Figure 3 ). As reported in our prior studies [ 24 , 25 ], the intraepithelial densities of all three TIL subsets were higher in triple negative subsets (TNNB and Basal-like) compared to the rest of the cohort. PD-L1 positive status tended to be associated with higher TIL density in all subsets.…”

Section: Resultssupporting

confidence: 84%

PD-L1 and intratumoral immune response in breast cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

PurposePD-L1 is thought to play an important role in the antitumor immune response. In this study, we investigated the expression of PD-L1 within breast tumor subsets to better define its prognostic significance.MethodsImmunohistochemistry was performed to determine PD-L1 tumor cell expression and to enumerate CD8, CD4 and CD68 tumor-infiltrating leucocytes (TIL) in a cohort of 443 breast cancers categorized by molecular subtype.ResultsAcross the entire cohort, PD-L1 tumor cell expression was observed in 73/443 (16.5%) cases and associated with known indicators of poor prognosis, including low patient age, high tumor grade, ER/PR negative status, but not with outcome. However, in the Triple Negative breast cancer subset PD-L1 was associated with better recurrence free survival (RFS) especially within the Basal-like subset (Hazard ratio = 0.39, 95% CI = 0.22 - 0.86, p = 0.018). Combined PD-L1/epithelial CD8 positive status was also strongly associated with better RFS and OS (Hazard ratio = 0.12, 95% CI = 0.10 - 0.71, p = 0.010 and Hazard ratio = 0.11, 95% CI = 0.11 - 0.68, p = 0.006 respectively) in the Basal-like subgroup.ConclusionsPD-L1 expression is associated with better patient survival in Basal-like breast cancer.

show abstract

Section: Resultssupporting

confidence: 84%

PD-L1 and intratumoral immune response in breast cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…It indicated that CD44 expression may regulate anti-tumor immunity by suppressing CD4 expression. CD74, a transmembrane glycoprotein, associates with the major histocompatibility complex (MHC) Class II and plays important roles in the intratumoral immune response [27–29]. CD74 was overexpressed in thyroid malignancy, malignant pleural mesothelioma, and head and neck squamous cell carcinomas, and it is associated with advanced tumor stage [30–32].…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses

2016

Oncotarget

View full text Add to dashboard Cite

CD44 is a well-recognized stem cell biomarker expressed in colon and gastric cancer. In order to identify whether CD44 mRNA could be used as a prognostic marker in colon and gastric cancer, bioinformatic analyses were used in this study. cBioPortal analysis and COSMIC analysis were used to explore the CD44 mutation. CD44 mRNA levels were evaluated by using SAGE Genie tools and Oncomine analysis. Kaplan-Meier Plotter was performed to identify the prognostic roles of CD44 mRNA in these two cancers. In this study, first, we found that low alteration frequency of CD44 mRNA in colon and gastric cancer. Second, the high CD44 mRNA level was found in colon and gastric cancer, and it correlated with a benign survival rate in gastric cancer. Third, CD4 and CD74 may be used as markers to predict the prognosis of colon and gastric cancer. However, the deep mechanism(s) of these results remains unclear, further studies have to be performed in the future.

show abstract

“…Interestingly, among the transcripts most differentially expressed between K14.GFP+ and K14.GFP− cells, we found both new and known metastasis-associated genes ( Table 2 ). Genes including metallothionein-2 ( Mt2 ) [ 29 , 30 ], transmembrane glycoprotein nonmetastatic B ( Gpnmb ) [ 31 ], caveolin 1 ( Cav1 ) [ 32 ], Col6A1 [ 26 , 27 ], HLA-DR antigens-associated invariant chain ( Cd74 ) [ 33 , 34 ], secretory leukocyte peptidase inhibitor ( SLPI ) [ 35 ], carbonic anhydrase ( Car9 ), amphiregulin ( Areg ) [ 36 – 38 ], and peripheral myelin protein 22 ( PMP22 ) [ 39 ] have previously been reported in association with invasive and/or metastatic phenotypes or as markers for poor prognosis in human breast cancer.…”

Section: Resultsmentioning

confidence: 99%

Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo

et al. 2018

View full text Add to dashboard Cite

The contribution of basal and luminal cells to cancer progression and metastasis is poorly understood. We report generation of reporter systems driven by either keratin-14 (K14) or keratin-8 (K8) promoter that not only express a fluorescent protein but also an inducible suicide gene. Transgenic mice express the reporter genes in the right cell compartments of mammary gland epithelia and respond to treatment with toxins. In addition, we engineered the reporters into 4T1 metastatic mouse tumor cell line and demonstrate that K14+ cells, but not K14− or K8+, are both highly invasive in three-dimensional (3D) culture and metastatic in vivo. Treatment of cells in culture, or tumors in mice, with reporter-targeting toxin inhibited both invasive behavior and metastasis in vivo. RNA sequencing (RNA-seq), secretome, and epigenome analysis of K14+ and K14− cells led to the identification of amphoterin-induced protein 2 (Amigo2) as a new cell invasion driver whose expression correlated with decreased relapse-free survival in patients with TP53 wild-type (WT) breast cancer.

show abstract

CD74 and intratumoral immune response in breast cancer

Cited by 115 publications

References 47 publications

PD-L1 and intratumoral immune response in breast cancer

PD-L1 and intratumoral immune response in breast cancer

Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses

Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo

Contact Info

Product

Resources

About